Contribute Try STAT+ Today

After two delays, two documentaries, and enough podcast hours to fill even the longest of road trips, the Theranos saga is finally headed for the courtroom. Elizabeth Holmes, founder and former CEO of the disgraced testing company, will stand trial starting this week on charges of conspiracy and fraud. She is accused of lying to investors, patients, and the public as Theranos became a multibillion-dollar darling of Silicon Valley.

The trial is the summation of the decade-long cautionary tale that is Theranos, a company that raised hundreds of millions of dollars on a revolutionary premise that proved to be false, buoyed by its charismatic founder, credulous investors, and an adulatory public. Holmes’s fate is sure to resonate in the startup world, where self-appointed visionaries court massive investments with ambitions that don’t always comport with reality.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment